OM vs. AORT, CDRE, TNDM, ESTA, LQDA, SSII, FNA, BLFS, PLSE, and KMTS
Should you be buying Outset Medical stock or one of its competitors? The main competitors of Outset Medical include Artivion (AORT), Cadre (CDRE), Tandem Diabetes Care (TNDM), Establishment Labs (ESTA), Liquidia Technologies (LQDA), SS Innovations International (SSII), Paragon 28 (FNA), BioLife Solutions (BLFS), Pulse Biosciences (PLSE), and Kestra Medical Technologies (KMTS). These companies are all part of the "medical equipment" industry.
Outset Medical vs. Its Competitors
Outset Medical (NASDAQ:OM) and Artivion (NYSE:AORT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.
Artivion has a net margin of -5.49% compared to Outset Medical's net margin of -98.74%. Artivion's return on equity of 3.63% beat Outset Medical's return on equity.
86.4% of Artivion shares are owned by institutional investors. 2.4% of Outset Medical shares are owned by insiders. Comparatively, 8.1% of Artivion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Artivion has higher revenue and earnings than Outset Medical. Artivion is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.
Outset Medical has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, Artivion has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.
Outset Medical currently has a consensus price target of $27.00, indicating a potential upside of 29.19%. Artivion has a consensus price target of $32.40, indicating a potential upside of 5.92%. Given Outset Medical's higher possible upside, analysts clearly believe Outset Medical is more favorable than Artivion.
In the previous week, Outset Medical and Outset Medical both had 1 articles in the media. Artivion's average media sentiment score of 1.70 beat Outset Medical's score of 0.37 indicating that Artivion is being referred to more favorably in the news media.
Summary
Artivion beats Outset Medical on 12 of the 15 factors compared between the two stocks.
Get Outset Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Outset Medical Competitors List
Related Companies and Tools
This page (NASDAQ:OM) was last updated on 7/9/2025 by MarketBeat.com Staff
